Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Quality of life and functional improvements with efanesoctocog alfa in patients with moderate-to-severe Hemophilia A: A real-world survey

View Full Paper
Ask AI
Bookmark
Share

Authors

MEMiguel A. EscobarUniversidad del SalvadorEME. MortonAdelphi Group (United Kingdom)DBDuygu BozkayaSanofi (United States)

Discussion

Loading...

Member takes

Overview

Real-world data show efanesoctocog alfa enhances patient-reported outcomes in hemophilia A, indicating improved quality of life and reduced preventive measures.

Key Points

  • To assess real-world patient-reported outcomes for efanesoctocog alfa in moderate-to-severe Hemophilia A patients.
  • Cross-sectional survey conducted via the Adelphi Real World Hemophilia Patient Survey
  • Gathered data on demographics, treatment satisfaction, and clinical outcomes
  • Included adult males with moderate-to-severe Hemophilia A receiving efanesoctocog alfa for at least 6 months
  • 93.5% of patients were satisfied with efanesoctocog alfa
  • Daily functioning improved with 51.6% reporting no difficulty after treatment
  • Need for preventive measures decreased from 19.4% to 58.1% post-treatment

Cite This Study

Escobar et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e110https://doi.org/10.1182/blood-2025-4846
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Unmet needs despite standard-of-care prophylaxis in Hemophilia A: improved outcomes after switching to Efanesoctocog Alfa2026
  2. 2Tailored prophylaxis in severe hemophilia A: Real-world experience with efanesoctocog alfa2025
  3. 3Comprehensive Assessment of the Transition to Efanesoctocog Alfa Prophylaxis in a Paediatric Haemophilia A Cohort2026
  4. 4Clinical experience with efanesoctocog alfa in patients with uncover needs on emicizumab2025
  5. 5Beyond Standard Half‐Life: Real‐world Pharmacokinetics of Efanesoctocog Alfa in a Single Centre2026